Top

Supportive Care in Cancer

Published in:

01-12-2021 | Original Article

Association of co-morbidities with financial hardship in survivors of adult cancer

Authors: Matthew J. Fastiggi, Jin-ah Sim, I-Chan Huang

Published in: Supportive Care in Cancer | Issue 12/2021

Abstract

Purpose

To evaluate the impact of co-morbidities on financial hardship in adult cancer survivors and the role of health insurance and a usual source of care (i.e., a particular doctor’s office/health center/other place that the person usually goes if he/she is sick or needs advice) in relieving this impact.

Methods

Using the Medical Expenditure Panel Survey, we estimated prevalence of two financial hardships, out-of-pocket (OOP) burden and financial worry, among 1196 adult cancer survivors. A modified Charlson co-morbidity index (CCI) assessed co-morbidities, which represent a medical event (e.g., a doctor’s appointment) associated with co-morbid conditions within the past 1 year. Multivariable logistic regression tested the influence of health insurance and a usual source of care on associations of co-morbidities with financial hardship by middle/high vs. low-income families and by working vs. retirement-age individuals.

Results

Years since cancer diagnosis ranged from 0 to 76 years (mean: 10.3, SD: 9.8), 10 and 25% of survivors experienced OOP burden and financial worry. For OOP burden, increased CCI was a risk factor among survivors of low-income families, ORs: 1.91 (95% CI: 1.06, 3.46) for a CCI 1–2 and 3.37 (95% CI: 1.72, 6.61) for a CCI ≥ 3 vs. CCI of 0. For financial worry, increased CCI was a risk factor among working-age survivors, ORs: 1.58 (95% CI: 1.02, 2.47) for a CCI 1–2 and 2.15 (95% CI: 1.19, 3.87) for a CCI ≥ 3 vs. CCI of 0. However, having health insurance and a usual source of care did not mitigate impact of co-morbidities on financial hardship (P values > 0.05).

Conclusions

Impact of co-morbidities on OOP and financial worry burden was greatest in survivors of low-income families and working-age, respectively. Health insurance and a usual source of care did not relieve the impact of co-morbidities on financial hardship.

Implications

Effective strategies are warranted to mitigate financial hardship for survivors.

Available only for authorised users

Carver JR et al (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25(25):3991–4008CrossRef

Stein KD, Syrjala KL, Andrykowski MA (2008) Physical and psychological long-term and late effects of cancer. Cancer 112(11 Suppl):2577–2592CrossRef

Harrington CB et al (2010) It’s not over when it’s over: long-term symptoms in cancer survivors–a systematic review. Int J Psychiatry Med 40(2):163–181

Weaver KE et al (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev, 21(11): 2108–17

Gegechkori N, Haines L, Lin JJ (2017) Long-term and latent side effects of specific cancer types. Med Clin North Am 101(6):1053–1073CrossRef

Kent EE et al (2013) Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119(20):3710–3717CrossRef

Kale HP, Carroll NV (2016) Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122(8):283–289CrossRef

Yabroff KR et al (2016) Financial hardship associated with cancer in the United States: Findings from a population-based sample of adult cancer survivors. J Clin Oncol 34(3):259–267CrossRef

Han X et al (2020) Medical financial hardship intensity and financial sacrifice associated with cancer in the United States. Cancer Epidemiol Biomarkers Prev 29(2):308–317CrossRef

10.

Altice CK et al. (2017) Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 109(2)

11.

Zheng Z et al (2019) Medical financial hardship among cancer survivors in the United States. Cancer 125(10):1737–1747CrossRef

12.

Bernard DS, Farr SL, Fang Z (2011) National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 29(20):2821–2826CrossRef

13.

Whitney RL et al (2016) Predictors of financial difficulties and work modifications among cancer survivors in the United States. J Cancer Surviv 10(2):241–250CrossRef

14.

Yabroff KR et al (2004) Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 96(17):1322–1330CrossRef

15.

Zafar SY et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18(4):381–390CrossRef

16.

Ramsey SD et al (2016) Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34(9):980–986CrossRef

17.

Huang IC et al (2019) Determinants and consequences of financial hardship among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. J Natl Cancer Inst 111(2): 189–200

18.

Jones SMW et al (2019) Comorbidity is associated with higher risk of financial burden in Medicare beneficiaries with cancer but not heart disease or diabetes. Medicine (Baltimore) 98(1):e14004CrossRef

19.

Guy GP Jr et al (2017) Economic burden of chronic conditions among survivors of cancer in the United States. J Clin Oncol 35(18):2053–2061CrossRef

20.

Bhakta N et al (2017) The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 390(10112):2569–2582CrossRef

21.

Halpern MT et al (2008) Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 9(3):222–231CrossRef

22.

Baicker K et al (2013) The Oregon experiment–effects of Medicaid on clinical outcomes. N Engl J Med 368(18):1713–1722CrossRef

23.

Starfield B, Shi L, Macinko J (2005) Contribution of primary care to health systems and health. Milbank Q 83(3):457–502CrossRef

24.

Sabatino SA et al (2021) Cancer screening test receipt - United States, 2018. MMWR Morb Mortal Wkly Rep 70(2):29–35CrossRef

25.

Cohen JW, Cohen SB, Banthin JS (2009) The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice. Med Care 47(7 Suppl 1):S44-50CrossRef

26.

Yabroff KR et al (2012) The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv 6(4):407–419CrossRef

27.

Hwang S (2014) A National Study of Health Services Utilization and Cost of Care with SAS®: Analyses from the 2011 Medical Expenditure Panel Survey

28.

D’Hoore W, Bouckaert A, Tilquin C (1996) Practical considerations on the use of the charlson comorbidity index with administrative data bases. J Clin Epidemiol 49(12):1429–1433CrossRef

29.

Louwman WJ et al (2010) A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 103(11):1742–1748CrossRef

30.

Hewitt M, Rowland JH, Yancik R (2003) Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 58(1):82–91CrossRef

31.

Rim SH et al (2016) The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review. Expert Rev Pharmacoecon Outcomes Res 16(5):579–589CrossRef

32.

Ramsey S et al (2013) Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32(6):1143–1152CrossRef

33.

Davidoff AJ et al (2013) Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 119(6):1257–1265CrossRef

34.

Claxton GLL, Sawyer B (2018) Increases in cost-sharing payments continue to outpace wage growth. Peterson-Kaiser Health System Tracker. https://www.healthsystemtracker.org/brief/increases-in-cost-sharing-payments-have-far-outpaced-wage-growth/#item-start. Accessed 1 Aug 2018

35.

Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the ‘silver tsunami’: prevalence trajectories and co-morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25(7):1029–1036CrossRef

Title: Association of co-morbidities with financial hardship in survivors of adult cancer
Authors: Matthew J. Fastiggi
Jin-ah Sim
I-Chan Huang
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06313-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications

Please log in to get access to this content

Other articles of this Issue 12/2021

Perceptions and acceptance of telemedicine among medical oncologists before and during the COVID-19 pandemic in Turkey

Psychological distress and lower health-related quality of life are associated with need for dietary support among colorectal cancer survivors with overweight or obesity

Mastication, swallowing, and salivary flow in patients with head and neck cancer: objective tests versus patient-reported outcomes

A hybrid model of acute unscheduled cancer care provided by a hospital-based acute care clinic and the emergency department: a descriptive study

Goals of care discussions: perceptions of radiation and medical oncologists

Survey of practices for the clinical management of febrile neutropenia in children in hematology-oncology units in Latin America

Keynote webinar | Spotlight on antibody–drug conjugates in cancer